Managing Patients on PCSK9 Inhibitors

By Lauren Santye, Assistant Editor

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses utilization management issues with a PCSK9 inhibitor regimen for high cholesterol.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses utilization management issues with a PCSK9 inhibitor regimen for high cholesterol.

Related Videos
View All
Related Content

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Phase 3 Trial Showed Zolbetuximab Significantly Improved Survival In Patients with Metastatic Gastric, Gastroesophageal Cancers

January 26th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

HIV Antiviral Therapies May Have Different Metabolic Signature

January 23rd 2023

FDA Grants Rare Pediatric Disease Designation to OR-440 for Treatment of Adrenocortical Carcinoma

January 23rd 2023

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Phase 3 Trial Showed Zolbetuximab Significantly Improved Survival In Patients with Metastatic Gastric, Gastroesophageal Cancers

January 26th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

HIV Antiviral Therapies May Have Different Metabolic Signature

January 23rd 2023

FDA Grants Rare Pediatric Disease Designation to OR-440 for Treatment of Adrenocortical Carcinoma

January 23rd 2023

MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal Cancer

January 27th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Phase 3 Trial Showed Zolbetuximab Significantly Improved Survival In Patients with Metastatic Gastric, Gastroesophageal Cancers

January 26th 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

HIV Antiviral Therapies May Have Different Metabolic Signature

January 23rd 2023

FDA Grants Rare Pediatric Disease Designation to OR-440 for Treatment of Adrenocortical Carcinoma

January 23rd 2023
About Us
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.